Use of Chinese Medicine and Subsequent Surgery in Women with Uterine Fibroid: A Retrospective Cohort Study
Table 3
Incidence and relative incidence of surgery for CM users and nonusers.
CM nonusers
CM users
IRRb
(95% CI)
Patients with surgery
Person-years
IRa
Patients with surgery
Person-years
IR
Overall
2074
19994
103.73
1607
90744
17.71
0.17
(0.16–0.18)***
Age, years
<20
0
144
0.00
0
843
0.00
—
20–29
66
1578
41.83
84
8849
9.49
0.23
(0.16–0.31)***
30–39
509
5390
94.43
636
26484
24.01
0.25
(0.23–0.29)***
40–49
1281
9488
135.01
807
41316
19.53
0.14
(0.13–0.16)***
≥50
218
3394
64.23
80
13252
6.04
0.09
(0.07–0.12)***
Income, US$ per month
<564.3
516
5401
95.54
406
24169
16.80
0.18
(0.15–0.20)***
564.3–656.5
415
3854
107.68
334
18075
18.48
0.17
(0.15–0.20)***
656.6–779.6
671
5268
127.37
469
26095
17.97
0.14
(0.13–0.16)***
≥779.7
472
5470
86.29
398
22406
17.76
0.21
(0.18–0.24)***
Occupational status
White collar
1094
11524
94.93
899
52095
17.26
0.18
(0.17–0.20)***
Blue collar
779
6078
128.17
559
29825
18.74
0.15
(0.13–0.16)***
Others
201
2392
84.03
149
8824
16.89
0.20
(0.16–0.25)***
Area
Northern Taiwan
946
11161
84.76
618
41349
14.95
0.18
(0.16–0.20)***
Central Taiwan
361
2137
168.93
368
17166
21.44
0.13
(0.11–0.15)***
Southern Taiwan
682
5759
118.42
549
28345
19.37
0.16
(0.15–0.18)***
Eastern Taiwan and offshore islands
85
935
90.91
72
3884
18.54
0.20
(0.15–0.28)***
Comorbidity
Excessive menstruation
No
1653
16616
99.48
1056
71005
14.87
0.15
(0.14–0.16)***
Yes
421
3378
124.63
551
19739
27.91
0.22
(0.20–0.25)***
Iron-deficiency anemia
No
1800
18054
99.70
1225
79864
15.34
0.15
(0.14–0.17)***
Yes
274
1940
141.24
382
10880
35.11
0.25
(0.21–0.29)***
Dysmenorrhea
No
1776
17481
101.60
1072
72183
14.85
0.15
(0.14–0.16)***
Yes
298
2512
118.63
535
18562
28.82
0.24
(0.21–0.28)***
Infertility
No
2072
19929
103.97
1592
90011
17.69
0.17
(0.16–0.18)***
Yes
2
65
30.77
15
733
20.46
0.67
(0.15–2.91)
aIR: incidence rate per 1,000 people.
bIRR: incidence rate ratio, compared to CM nonusers.
***
.
We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.
